Item 1.01 Entry into a Material Definitive Agreement.
On December 1, 2020, SunHydrogen, Inc. (the "Company") entered into a securities
purchase agreement ("Purchase Agreement") with the purchaser set forth on the
signature page thereto (the "Purchaser") for the purchase and sale of an
aggregate of 120,000,000 shares of the Company's common stock (the "Shares"),
and warrants to purchase an aggregate of up to 120,000,000 shares of common
stock ("Warrants"), in a registered direct offering at a combined purchase price
of $0.075 per Share and Warrant, for an aggregate gross proceeds to the Company
of $9,000,000. The Warrants will be exercisable for a period commencing upon
issuance and expiring 30 months from issuance, at an exercise price of $0.075
per share.
Pursuant to an engagement letter (the "Engagement Letter") dated November 30,
2020 by and between the Company and H.C. Wainwright & Co., LLC ("Wainwright"),
the Company engaged Wainwright to act as the Company's exclusive placement agent
in connection with the registered direct offering. Pursuant to the engagement
agreement, the Company agreed to pay Wainwright a cash fee of 7.0% of the gross
proceeds the Company receives under the Purchase Agreement. The Company also
agreed to pay Wainwright (i) a management fee equal to 1.0% of the gross
proceeds raised in the offering; (ii) $85,000 for non-accountable expenses; and
(iii) closing costs of $5,000. In addition, the Company agreed to issue to
Wainwright (or its designees) placement agent warrants (the "Placement Agent
Warrants") to purchase a number of shares equal to 7.0% of the aggregate number
of Shares sold under the Purchase Agreement., or warrants to purchase up to an
aggregate of 8,400,000 shares. The Placement Agent Warrants generally will have
the same terms as the Warrants, except they will have an exercise price of
$0.0938 and the Placement Agent Warrants and the shares of common stock issuable
thereunder are not registered under the Securities Act of 1933, as amended.
The gross proceeds from the registered direct offering are expected to be
approximately $9.0 million, before deducting fees payable to the placement agent
and other estimated offering expenses. The Company intends to use the net
proceeds primarily to accelerate the development of its breakthrough
nanoparticle hydrogen generation technology, as well as for working capital and
general corporate purposes. The registered direct offering is expected to close
on or about December 3, 2020, subject to the satisfaction of customary closing
conditions.
The Shares and Warrants (and underlying shares) were offered, and will be
issued, pursuant to the Prospectus Supplement, dated December 1, 2020, to the
Prospectus included in the Company's Registration Statement on Form S-3
(Registration No. 333- 239632) filed with the Securities and Exchange Commission
on July 2, 2020 and declared effective on July 8, 2020, and Registration
Statement on Form S-3MEF (File No. 333- 251064) filed pursuant to Rule 462(b).
Sichenzia Ross Ference LLP, counsel to the Company, has issued an opinion to the
Company regarding the validity of the securities to be issued in the offering. A
copy of the opinion is filed as Exhibit 5.1 to this Current Report on Form 8-K.
The foregoing summaries of the terms of the Purchase Agreement, Warrants,
Placement Agent Warrants, and Engagement Letter described herein are subject to,
and qualified in their entirety by, such documents, which are incorporated
herein by reference.
Item 1.02 Termination of a Material Definitive Agreement
On September 23, 2020, the Company filed a Current Report on Form 8-K to report
it had entered into a purchase agreement dated September 21, 2020 (the "GHS
Agreement") with GHS Investments, LLC ("GHS"). On December 1, 2020, the Company
terminated the GHS Agreement. Under the GHS Agreement, the Company had the right
to sell, in the Company's discretion (subject to the terms and conditions of the
GHS Agreement), up to an aggregate of $4,000,000 of common stock to GHS. As of
December 1, 2020, the Company sold $1,700,000 pursuant to the GHS Agreement.
1
Item 3.02 Unregistered Sales of Equity Securities.
The information set forth in Item 1.01 is incorporated by reference into this
Item 3.02. In connection with the sale of the Placement Agent Warrant, the
Company relied upon the exemption from registration provided by Section 4(a)(2)
of the Securities Act of 1933, as amended, for transactions not involving a
public offering.
Item 8.01 Other Events.
On December 1, 2020, the Company issued a press release regarding the registered
direct offering. A copy of the press release is attached as Exhibit 99.1 hereto.
Item 9.01 Financial Statements and Exhibits.
Exhibit No Exhibit
5.1 Opinion of Sichenzia Ross Ference LLP
10.1 Form of Securities Purchase Agreement
10.2 Form of Warrant
10.3 Form of Placement Agent Warrant
10.4 Engagement Letter.
99.1 Press release
2
© Edgar Online, source Glimpses